Cytek Biosciences, Inc.
Cytek Biosciences, Inc. (CTKB) Financial Performance & Income Statement Overview
Analyze Cytek Biosciences, Inc. (CTKB) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Cytek Biosciences, Inc. (CTKB) Income Statement & Financial Overview
Explore comprehensive income reports for Cytek Biosciences, Inc. CTKB, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $41.46M | $57.48M | $51.50M | $46.62M |
| Cost of Revenue | $21.30M | $23.82M | $22.50M | $21.18M |
| Gross Profit | $20.16M | $33.65M | $29.005M | $25.44M |
| Gross Profit Ratio | $0.49 | $0.59 | $0.56 | $0.55 |
| R&D Expenses | $9.72M | $9.72M | $9.88M | $10.001M |
| SG&A Expenses | $25.41M | $20.94M | $23.37M | $23.96M |
| Operating Expenses | $35.13M | $30.67M | $33.25M | $33.96M |
| Total Costs & Expenses | $56.43M | $54.49M | $55.75M | $55.14M |
| Interest Income | $508000.00 | $6.15M | $1.43M | $1.42M |
| Interest Expense | $291000.00 | $0.00 | $119000.00 | $134000.00 |
| Depreciation & Amortization | $0.00 | $2.74M | $2.81M | $2.48M |
| EBITDA | -$14.97M | $7.12M | $3.08M | -$4.57M |
| EBITDA Ratio | -$0.36 | $0.12 | $0.06 | -$0.10 |
| Operating Income | -$14.97M | $2.99M | -$4.25M | -$8.53M |
| Operating Income Ratio | -$0.36 | $0.05 | -$0.08 | -$0.18 |
| Other Income/Expenses (Net) | $3.71M | $7.34M | $4.41M | $1.34M |
| Income Before Tax | -$11.27M | $10.32M | $157000.00 | -$7.19M |
| Income Before Tax Ratio | -$0.27 | $0.18 | $0.003 | -$0.15 |
| Income Tax Expense | $136000.00 | $680000.00 | -$784000.00 | $3.25M |
| Net Income | -$11.40M | $9.64M | $941000.00 | -$10.43M |
| Net Income Ratio | -$0.28 | $0.17 | $0.02 | -$0.22 |
| EPS | -$0.09 | $0.07 | $0.007 | -$0.08 |
| Diluted EPS | -$0.09 | $0.07 | $0.007 | -$0.08 |
| Weighted Avg Shares Outstanding | $128.34M | $129.21M | $131.004M | $131.44M |
| Weighted Avg Shares Outstanding (Diluted) | $128.34M | $129.21M | $132.79M | $131.44M |
The company's financials show resilient growth, with revenue advancing from $46.62M in Q2 2024 to $41.46M in Q1 2025. Gross profit remained healthy with margins at 49% in Q1 2025 compared to 55% in Q2 2024. Operating income hit -$14.97M last quarter, sustaining a consistent -36% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$14.97M. Net income dropped to -$11.40M, while earnings per share reached -$0.09. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan